Shares of Savara Inc (NASDAQ:SVRA) have been given a consensus recommendation of “Hold” by the eight research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $26.40.
A number of analysts have weighed in on SVRA shares. BidaskClub cut Savara from a “sell” rating to a “strong sell” rating in a research report on Friday, March 30th. ValuEngine raised Savara from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 14th. Ladenburg Thalmann started coverage on Savara in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Canaccord Genuity set a $25.00 price objective on Savara and gave the stock a “buy” rating in a research note on Friday, February 16th.
In other news, CFO David L. Lowrance sold 7,000 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $12.88, for a total transaction of $90,160.00. Following the transaction, the chief financial officer now owns 33,994 shares of the company’s stock, valued at $437,842.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $12.85, for a total value of $321,250.00. Following the transaction, the insider now directly owns 219,216 shares in the company, valued at approximately $2,816,925.60. The disclosure for this sale can be found here. 6.93% of the stock is currently owned by insiders.
Shares of NASDAQ:SVRA opened at $8.61 on Thursday. Savara has a fifty-two week low of $4.60 and a fifty-two week high of $17.19. The firm has a market capitalization of $269.56, a price-to-earnings ratio of -4.89 and a beta of 0.04. The company has a current ratio of 16.28, a quick ratio of 16.28 and a debt-to-equity ratio of 0.13.
Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, March 14th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. research analysts predict that Savara will post -1.43 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3340935/analysts-set-savara-inc-svra-target-price-at-26-40.html.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.